Retatrutide: Results, Side Effects and FDA Status

TRIUMPH-1, published in September 2026, randomized 2,339 adults with obesity without diabetes. At 80 weeks, mean weight reduction was 17.6%, 23.7% and 25.0% with 4, 9 and 12 mg respectively, versus 3.9% with placebo. These are treatment-regimen, intention-to-treat estimates ⁹.

TRIUMPH-2 also published in September 2026. Its 1,152 participants had type 2 diabetes and a BMI of at least 27. At 80 weeks, treatment-regimen mean weight reductions were 11.9%, 16.8% and 18.8% with 4, 9 and 12 mg, versus 5.1% on placebo ¹⁰.

The earlier TRANSCEND-T2D-1 study enrolled 537 adults with type 2 diabetes inadequately controlled through diet and exercise. At 40 weeks, the 12 mg group had a 15.3% mean weight reduction versus 2.6% on placebo under the treatment-regimen analysis. Its primary endpoint was blood-sugar control, rather than weight ³.

These are separate studies, not a sequence in which one result proves another wrong. Nor do they establish that retatrutide is better than an approved alternative. The relevant comparison includes approved options and their specific evidence.

TRIUMPH-5 directly compares the two medicines. The registry checked October 13, 2026 lists it as active, not recruiting, with an estimated 800 participants and December 2026 completion; it has no posted results ¹². A projected completion date is not a promised publication date. Comparing the percentages from separate trials cannot resolve which treatment works better for comparable patients.

Digestive symptoms dominate the published safety findings. The earlier obesity trial also recorded dose-related heart-rate increases, which peaked at 24 weeks and then declined ¹. The newer trials provide more information, but they do not make long-term or rare risks disappear. The safety summary above separates findings by trial rather than pooling unlike populations.

The body-composition substudy found that lean tissue accounted for a proportion of weight loss similar to other obesity treatments; it did not establish that retatrutide preserves all muscle ⁵. The liver substudy measured liver-fat changes in a selected group, rather than proving every person with liver disease will benefit ⁶. A urinary-tract-infection letter is correspondence, not an additional randomized trial ⁷.

As checked October 13, 2026, FDA states that retatrutide is not a component of an approved medicine and cannot be compounded under federal law ¹¹. Successful trial results are evidence for regulators to evaluate, not an approval or a retail launch date. There is no FDA-approved retatrutide prescribing label or approved retail product price to compare.

Clinical research and expanded access are different from commercial sales. Lilly's single-patient expanded-access record (NCT07629401), checked October 13, is listed as available, but eligibility is narrow and requests go through a treating physician ¹³. A record marked available does not mean every patient qualifies or will receive the drug.

Before-and-after photos cannot establish which substance a person received, its dose, or what else changed. Likewise, a supplier's label or appearance in a drug-listing database should not be mistaken for FDA approval. The meaningful evidence comes from identified study medicine, defined participants and measured outcomes—not from the name printed on an online vial.